Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy

Li, Ruijuan; Helbig, L.; Fu, Jun; Bian, Xiaoying; Herrmann, Jennifer; Baumann, Michaël; Stewart, A. Francis; Müller, Rolf; Li, Aiying; Zips, Daniel; Zhang, Youming

doi:10.1016/j.resmic.2018.11.001

Cited by 56 publications

(47 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the aim of the present work was to achieve a better understanding of the mechanisms of regulation of colibactin expression and their implications for the biological role of colibactin. The observation that the colibactin biosynthetic pathway can produce different small compounds, such as an analgesic peptide, which can have completely different effects than colibactin itself (14,15,17,22), serves as a great motivator to advance the elucidation of the factors and processes that contribute to the regulation of colibactin expression. Our understanding of the regulation of pks island expression revolves around the activity of its proposed key regulator, ClbR.…”

mentioning

confidence: 99%

ClbR Is the Key Transcriptional Activator of Colibactin Gene Expression in Escherichia coli

Wallenstein

Rehm

Brinkmann

et al. 2020

mSphere

Self Cite

View full text Add to dashboard Cite

The nonribosomal peptide/polyketide hybrid colibactin can be considered a bacterial virulence factor involved in extraintestinal infection and also a procarcinogen. Nevertheless, and despite its genotoxic effect, colibactin expression can also inhibit bacterial or tumor growth and correlates with probiotic anti-inflammatory and analgesic properties. Although the biological function of this natural compound has been studied extensively, our understanding of the regulation of colibactin expression is still far from complete. We investigated in detail the role of regulatory elements involved in colibactin expression and in the growth conditions that promote colibactin expression. In this way, our data shed light on the regulatory mechanisms involved in colibactin expression and may support the expression and purification of this interesting nonribosomal peptide/polyketide hybrid for further molecular characterization.

show abstract

mentioning

confidence: 99%

ClbR Is the Key Transcriptional Activator of Colibactin Gene Expression in Escherichia coli

Wallenstein

Rehm

Brinkmann

et al. 2020

mSphere

Self Cite

View full text Add to dashboard Cite

show abstract

“…This engineered strain suppressed the growth of tumors and prevented pulmonary metastasis in mice 63 . Similarly, Li et al engineered an EcN chassis to produce cytotoxic compounds, including colibactin, glidobactin, and luminmide to suppress tumor growth in a mouse model 64 . More recently, Ho et al engineered EcN for the treatment of colorectal cancer by expressing HlpA, a protein that binds specifically to a heparan sulphate proteoglycan, enabling engineered EcN to specifically target polyps in a murine colorectal cancer model 65 .…”

Section: Design Of Engineered Therapeutic Strains For Solid Tumorsmentioning

confidence: 99%

Developing a new class of engineered live bacterial therapeutics to treat human diseases

et al. 2020

View full text Add to dashboard Cite

A complex interplay of metabolic and immunological mechanisms underlies many diseases that represent a substantial unmet medical need. There is an increasing appreciation of the role microbes play in human health and disease, and evidence is accumulating that a new class of live biotherapeutics comprised of engineered microbes could address specific mechanisms of disease. Using the tools of synthetic biology, nonpathogenic bacteria can be designed to sense and respond to environmental signals in order to consume harmful compounds and deliver therapeutic effectors. In this perspective, we describe considerations for the design and development of engineered live biotherapeutics to achieve regulatory and patient acceptance. Regulatory considerations for live biotherapeutic products Live biotherapeutic products (LBPs) are defined as live organisms designed and developed to treat, cure, or prevent a disease or condition in humans 10. Notably, LBPs exclude vaccines, filterable viruses, oncolytic viruses, and organisms used as vectors for transferring genes into the host. LBPs are distinguished from probiotic supplements on the basis of their labeling claims, as

show abstract

“…This involves imaging the expression of the therapeutic gene after it has been transferred to evaluate the efficiency of the treatment [13], [113]. Several studies in gene therapy have been conducted to monitor tumor phenomena using BLI including the imaging of metastasis [114], apoptosis [115], [116], tumor hypoxia [117]- [122], and angiogenesis [123].…”

Section: Dmentioning

confidence: 99%

Bioluminescence Imaging Applications in Cancer: A Comprehensive Review

AlSawaftah

Farooq

Dhou

et al. 2021

IEEE Rev. Biomed. Eng.

View full text Add to dashboard Cite

Bioluminescence imaging (BLI), an optical preclinical imaging modality, is an invaluable imaging modality due to its low-cost, high throughput, fast acquisition times, and functional imaging capabilities. BLI is being extensively used in the field of cancer imaging, especially with the recent developments in geneticengineering, stem cell, and gene therapy treatments. The purpose of this paper is to provide a comprehensive review of the principles, developments, and current status of BLI in cancer research. This paper covers the fundamental BLI concepts including BLI reporters and enzyme-substrate systems, data acquisition, and image characteristics. It reviews the studies discussing the use of BLI in cancer research such as imaging tumor-characteristic phenomena including tumorigenesis, metastasis, cancer metabolism, apoptosis, hypoxia, and angiogenesis, and response to cancer therapy treatments including chemotherapy, radiotherapy, immunotherapy, gene therapy, and stem cell therapy. The key advantages and disadvantages of BLI compared to other common imaging modalities are also discussed.

show abstract

Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy

Cited by 56 publications

References 29 publications

ClbR Is the Key Transcriptional Activator of Colibactin Gene Expression in Escherichia coli

ClbR Is the Key Transcriptional Activator of Colibactin Gene Expression in Escherichia coli

Developing a new class of engineered live bacterial therapeutics to treat human diseases

Bioluminescence Imaging Applications in Cancer: A Comprehensive Review

Contact Info

Product

Resources

About